Medscheme vs Bonitas: Court Battle Over Alleged Tender Fraud

Afrocentric subsidiary Medscheme is seeking to halt Bonitas Medical Scheme’s multibillion-rand administration and managed care tender process, alleging improper procurement practices. The legal challenge, filed in the Gauteng Division of the High Court in Johannesburg, centers on contracts related to South Africa’s second-largest open medical scheme, which serves approximately one million beneficiaries and manages roughly R20-billion in annual contributions.

Medscheme launched an urgent high court application in November 2025, requesting an interdict to suspend the tenders pending the outcome of a forensic investigation by the Council for Medical Schemes into alleged governance and procurement irregularities, according to court documents filed this week. The company claims that implementing the disputed awards could cause irreversible operational and financial harm.

The Council for Medical Schemes initiated a Section 43 analysis in November 2025, which reportedly indicated that the allegations against Bonitas warranted further investigation. Medscheme’s answering affidavit, released this week, details evidence supporting its claims of a tainted tender process. The company asserts that Bonitas’ procurement process was flawed, potentially compromising the integrity of the scheme.

Bonitas has not yet publicly responded to the specific allegations detailed in Medscheme’s affidavit. However, the medical scheme has previously stated that it believes its tender process was fair and transparent. A statement released by Medscheme on February 18, 2026, indicated that the High Court application was not an attempt to retain existing contracts, but rather to ensure a fair and legally sound procurement process.

The hearing in the Gauteng Division of the High Court is scheduled for Tuesday, March 3, 2026. The outcome of the case could significantly impact the administration and managed care services provided to Bonitas beneficiaries. The legal battle represents a significant clash between two major players in South Africa’s healthcare industry, with potential ramifications for governance and procurement standards within medical schemes.